Singular Genomics Systems (NASDAQ:OMIC) Trading 0.9% Higher – Should You Buy?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) rose 0.9% during mid-day trading on Monday . The stock traded as high as $19.90 and last traded at $19.80. 4,148 shares traded hands during trading, a decline of 75% from the average session volume of 16,293 shares. The stock had previously closed at $19.62.

Singular Genomics Systems Trading Down 0.6 %

The business’s 50 day simple moving average is $20.70 and its 200 day simple moving average is $14.15. The stock has a market cap of $49.46 million, a price-to-earnings ratio of -0.56 and a beta of 1.82. The company has a quick ratio of 6.67, a current ratio of 7.37 and a debt-to-equity ratio of 0.04.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($6.72) EPS for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 57.87%. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.74 million.

Institutional Trading of Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC grew its position in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,962 shares of the company’s stock after buying an additional 1,193 shares during the period. Geode Capital Management LLC owned approximately 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent quarter. Institutional investors own 65.80% of the company’s stock.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.